ATH-007 / Atheron Therapeutics - LARVOL DELTA

Discovery of ATH-007, a novel, potent and highly selective CCNE1 molecule glue shows robust anti-tumor activities and better safety profile (AACR 2026) - "In tumor model with CCNE1 amplification, ATH-007 shows tumor suppression activity even at low doses and inhibit tumor growth in a dose-dependent manner. Furthermore, the inhibitory activity against tumors is correlated with the degradation of CCNE1."

Clinical • Breast Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • Uterine Cancer • CCNE1 • CRBN • GSPT1 • IKZF1 • RB1